- RallyBio tries again for reverse merger, this time with Avenzo<figure><div><img src="https://imgproxy.divecdn.com/jnFfJ5RS6xuGM4eSgKJWCwh47VZKvpGyBiu3dqhXngw/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMjIwOTA5MTA5LmpwZ…BioPharma Dive · 1mo ago↗ source
- The cost of a PRV is twice as high as it was three years ago — and it’s likely to stay that wayHow much is a regulatory shortcut worth? The cost of a priority review voucher, which shortens the FDA’s standard review time by about four months, has roughly doubled in the last few years. The…Endpoints · 1mo ago↗ source
- Epigenetic editing shows promise against chronic hep B infectionsA new method of CRISPR-based gene editing shows promise in curtailing chronic hepatitis B infections. Its twist is to silence disease-causing genes without altering the underlying DNA. Tune Thera…